List of new medicines funded, or access widened, in 2020/21

OIA response

Thank you for your request dated 12 January 2022 under the Official Information Act 1982 (OIA) for information relating to new medicines funded, or access widened, as noted in our Year in Review report for 2020/21. You requested: 

…it was reported that Pharmac funded 13 new medicines and widened access to 19 medicines already funded. Could you please send me a list of what these decisions were? 

The table below provides data on new investment decisions that PHARMAC has made to 30 June 2021 for implementation in the financial year 2020/21.*** 

Investment decisions are classified as access widening (AW)* or new listings (NL)** 

Pharmaceutical (number of chemicals) Used to treat Decision type
Atomoxetine Attention deficit hyperactivity disorder (ADHD) AW
Infliximab Less severe presentations of plaque psoriasis AW
Mifepristone Medical abortion AW
Misoprostol Medical abortion AW
TNF-alpha inhibitors (infliximab, adalimumab, etanercept) Pyoderma gangrenosum AW
Enteral liquid peptide formula Children with impaired gastrointestinal (GI) function NL
High protein enteral feed 1.26 kcal/ml Patients with elevated protein needs NL
Lidocaine [lignocaine] 2% gel, urethral syringe Rectal administration for intractable rectal pain/tenesmus AW
Ticagrelor Neurological stenting AW
Methylphenidate Hydrocholoride Extended Release Attention deficit hyperactivity disorder (ADHD) first-line use. AW
Adalimumab, etanercept and tocilizumab Juvenile idiopathic arthritis AW
Dornase alfa Cystic fibrosis AW
Emicizumab Severe haemophilia A and high titre inhibitors NL
Pimecrolimus cream Atopic dermatitis of the eyelid NL
Desmopressin Treatment of central/cranial diabetes insipidus, nocturnal enuresis and nocturia AW
Empagliflozin (with and without metformin) People with type 2 diabetes who are at high risk of heart and kidney complications NL
Febuxostat Prevention of tumour lysis syndrome AW
Sirolimus Lymphovascular malformations and tuberous sclerosis complex complications AW
Valganciclovir Cytomegalovirus prophylaxis and treatment in transplant patients AW
Multiple Sclerosis Treatments (multiple medicines) Multiple sclerosis AW
Nitrofurantoin Urinary-tract infections NL
Rituximab Membranous nephropathy AW
Latanoprost with timolol Raised intra-ocular pressure (glaucoma) in patients not adequately responding to monotherapy NL
Ethinylestradiol with desogestrel Oral contraceptive AW
Secukinumab Psoriatic arthritis and ankylosing spondylitis AW
Bendamustine Relapsed or refractory Hodgkin’s Lymphoma AW
Carglumic acid Hyperammonaemia arising from severe organic acidaemia NL
Coenzyme Q10 Treating inborn errors of metabolism responsive to Coenzyme Q10 supplementation NL
Levocarnitine Treating inborn errors of metabolism responsive to Levocarnitine supplementation NL
Riboflavin Treating inborn errors of metabolism responsive to Riboflavin supplementation NL
Arginine Treating inborn errors of metabolism responsive to supplementation NL
Taurine Treating specific mitochondrial disorders responsive to supplementation NL

 *        Changes in access criteria for existing funded medicines, making them more accessible and/or available for a wider patient population(s).

**      Any medicine not currently listed on the Schedule and any new presentations (i.e. tablet, infusion, injection) that represent a significant shift in treatment options for patients.

***     Excludes temporary access widenings due to COVID-19 

We trust that this information answers your queries. We are making our information more freely available, so we now publish selected OIA responses (excluding personal details) on our website. Please get in touch with us if you have any questions about this.